A intervenção do enfermeiro especialista em enfermagem de reabilitação na promoção da transição para o papel de cuidador da pessoa dependente no autocuidado

Mestrado, Enfermagem de Reabilitação, 2014, Escola Superior de Enfermagem de LisboaFace ao envelhecimento da população em Portugal e à prevalência da doença crónica assiste-se, cada vez mais, a um maior número de pessoas dependentes no seu autocuidado. Pelas actuais políticas de saúde, bem como pela realidade social, constatasse que a pessoa com dependência no autocuidado permanece no seu domicílio, na sua comunidade. Mediante os estudos realizados no nosso país na última década, observasse que são os familiares, nomeadamente, os seus cônjuges ou filhos, que asseguram a maior parte dos cuidados relacionados com a higiene, alimentação, transferências e eliminação vesical e intestinal. Na maioria das vezes, os cuidadores vivenciam a experiência do cuidar pela primeira vez, isto é, o processo de transição para o papel de cuidador, um processo complexo, que incorre na alteração da sua vida, ocorrendo o fenómeno da sobrecarga do cuidador. O enfermeiro especialista em Enfermagem de Reabilitação, pelas competências definidas e regulamentadas pela Ordem dos Enfermeiros, intervém junto da pessoa e do seu cuidador para facilitar a transição para o papel de cuidador e a promoção do autocuidado, estabelecendo uma relação de parceria. O presente trabalho explana o percurso que desenvolvi para promover o papel de cuidador da pessoa dependente no autocuidado. Para o efeito concorreram o projecto de formação anteriormente elaborado; a realização dos ensinos clínicos, com supervisão de enfermeiro especialista; a pesquisa bibliográfica; e o pensamento reflexivo. Os cuidados de enfermagem de reabilitação assentaram no treino e supervisão de técnicas específicas do autocuidado quer para o cuidador, quer para o seu familiar; a supervisão das mesmas; o suporte emocional e referenciação para os serviços da comunidade. No decorrer dos ensinos clínicos a relação de proximidade estabelecida, permitiu uma boa adesão dos cuidadores e dos seus familiares aos cuidados de enfermagem de reabilitação, que se manifestou pela aquisição de habilidades e desenvolvimento de estratégias de coping pelos cuidadores

A efetividade do decúbito ventral na Acute Respiratory Distress Syndrome: revisão sistemática

Background: prone Position is a well-established evidence-based clinical practice in patients with Acute Respiratory Distress Syndrome undergoing invasive mechanical ventilation. Little evidence in non-intubated patients is known. Due to the increasing rate of acute respiratory distress syndrome, the need to know the effectiveness in non-intubated patients has emerged. Objective: to know the effectiveness of prone position in the treatment of acute respiratory distress syndrome in non-intubated adults. Methodology: Systematic reviews based on the manual of Joanna Briggs Institute and carried out using PICO strategy. Research conducted in August 2021 in the access platforms Web of Science, PubMed, and EBSCO Host. Selection was done after elimination of duplicates, title reading, reading of abstracts, and full texts according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram Results: 741 results were identified, and seven were included in the review. Conclusion: Early prone position is advantageous in non-intubated patients with mild and moderate acute respiratory distress syndrome. A risk intervention in non-intubated patients with Severe Acute Respiratory Distress Syndrome. Mortality/survival, physiological/clinical, adverse events/effects and functioning outcomes were identified as predictors of success/failure of prone position.Marco contextual: posición prona es una práctica clínica, basada en evidencia, conocida en pacientes con Síndrome de Dificultad Respiratoria Aguda con ventilación mecánica invasiva. Hay poca evidencia en pacientes no entubados. La creciente tasa de síndrome de distrés respiratorio agudo originó la necesidad de desarrollar esfuerzos para conocer su efectividad en pacientes no intubados. Objetivo: conocer la efectividad del decúbito prono en el tratamiento del síndrome de distrés respiratorio agudo en adultos no intubados. Metodología: revisión sistemática basadas en el manual del Instituto Joanna Briggs y mediante la estrategia PICO. La búsqueda ocurrió en agosto 2021 en las plataformas de acceso Web of Science, PubMed y EBSCO Host. Selección realizada por previa eliminación de duplicados, lectura de títulos, resúmenes y textos completos de acuerdo con el diagrama Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Resultados: se identificaron 741 resultados, siete incluyeron la revisión. Conclusión: la posición prona temprana demostró ser ventajosa en pacientes no intubados con Síndrome de Dificultad Respiratoria Aguda leve y moderado. Intervención riesgosa en pacientes no intubados con Síndrome de Dificultad Respiratoria Aguda grave. Indicadores de mortalidad/supervivencia, fisiológicos/clínicos, de eventos/efectos adversos e indicadores funcionales, fueron identificados como predictores de éxito/fracaso de la posición prono.Enquadramento: o decúbito ventral é uma prática clínica baseada na evidência que se encontra bem estabelecida em pacientes com Acute Respiratory Distress Syndrome submetidos a ventilação mecânica invasiva. Porém, existe parca evidência em pacientes não intubados. Face ao aumento da taxa de Acute Respiratory Distress Syndrome, emergiu a necessidade de conhecer a sua eficácia em pacientes não intubados. Objetivo: conhecer a efetividade do decúbito ventral no tratamento da Acute Respiratory Distress Syndrome em adultos não intubados. Metodologia: revisão sistemática fundamentada no manual de Joanna Briggs Institute, com recurso à estratégia PICO. Pesquisa realizada em agosto de 2021, nas plataformas de acesso Web of Science, PubMed e EBSCO Host. Seleção realizada após eliminação de duplicados, leitura do título, de resumos e textos integrais de acordo com o diagrama Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Resultados: identificaram-se 741 resultados, sendo sete os incluídos na revisão. Conclusão: O decúbito ventral precoce revelou-se vantajoso em pacientes não intubados com Acute Respiratory Distress Syndrome ligeira e moderada. É uma intervenção de risco em pacientes não intubados com Acute Respiratory Distress Syndrome grave. Foram identificados indicadores de mortalidade/ sobrevida, fisiológicos/ clínicos, de eventos/ efeitos adversos e indicadores funcionais como preditores de sucesso/ insucesso do decúbito ventral

Pervasive gaps in Amazonian ecological research

Biodiversity loss is one of the main challenges of our time,1,2 and attempts to address it require a clear un derstanding of how ecological communities respond to environmental change across time and space.3,4 While the increasing availability of global databases on ecological communities has advanced our knowledge of biodiversity sensitivity to environmental changes,5–7 vast areas of the tropics remain understudied.8–11 In the American tropics, Amazonia stands out as the world’s most diverse rainforest and the primary source of Neotropical biodiversity,12 but it remains among the least known forests in America and is often underrepre sented in biodiversity databases.13–15 To worsen this situation, human-induced modifications16,17 may elim inate pieces of the Amazon’s biodiversity puzzle before we can use them to understand how ecological com munities are responding. To increase generalization and applicability of biodiversity knowledge,18,19 it is thus crucial to reduce biases in ecological research, particularly in regions projected to face the most pronounced environmental changes. We integrate ecological community metadata of 7,694 sampling sites for multiple or ganism groups in a machine learning model framework to map the research probability across the Brazilian Amazonia, while identifying the region’s vulnerability to environmental change. 15%–18% of the most ne glected areas in ecological research are expected to experience severe climate or land use changes by 2050. This means that unless we take immediate action, we will not be able to establish their current status, much less monitor how it is changing and what is being lostinfo:eu-repo/semantics/publishedVersio

ARIA digital anamorphosis : Digital transformation of health and care in airway diseases from research to practice

Digital anamorphosis is used to define a distorted image of health and care that may be viewed correctly using digital tools and strategies. MASK digital anamorphosis represents the process used by MASK to develop the digital transformation of health and care in rhinitis. It strengthens the ARIA change management strategy in the prevention and management of airway disease. The MASK strategy is based on validated digital tools. Using the MASK digital tool and the CARAT online enhanced clinical framework, solutions for practical steps of digital enhancement of care are proposed.Peer reviewe

Pervasive gaps in Amazonian ecological research

Biodiversity loss is one of the main challenges of our time,1,2 and attempts to address it require a clear understanding of how ecological communities respond to environmental change across time and space.3,4 While the increasing availability of global databases on ecological communities has advanced our knowledge of biodiversity sensitivity to environmental changes,5,6,7 vast areas of the tropics remain understudied.8,9,10,11 In the American tropics, Amazonia stands out as the world's most diverse rainforest and the primary source of Neotropical biodiversity,12 but it remains among the least known forests in America and is often underrepresented in biodiversity databases.13,14,15 To worsen this situation, human-induced modifications16,17 may eliminate pieces of the Amazon's biodiversity puzzle before we can use them to understand how ecological communities are responding. To increase generalization and applicability of biodiversity knowledge,18,19 it is thus crucial to reduce biases in ecological research, particularly in regions projected to face the most pronounced environmental changes. We integrate ecological community metadata of 7,694 sampling sites for multiple organism groups in a machine learning model framework to map the research probability across the Brazilian Amazonia, while identifying the region's vulnerability to environmental change. 15%–18% of the most neglected areas in ecological research are expected to experience severe climate or land use changes by 2050. This means that unless we take immediate action, we will not be able to establish their current status, much less monitor how it is changing and what is being lost

Pervasive gaps in Amazonian ecological research

Biodiversity loss is one of the main challenges of our time,1,2 and attempts to address it require a clear understanding of how ecological communities respond to environmental change across time and space.3,4 While the increasing availability of global databases on ecological communities has advanced our knowledge of biodiversity sensitivity to environmental changes,5,6,7 vast areas of the tropics remain understudied.8,9,10,11 In the American tropics, Amazonia stands out as the world's most diverse rainforest and the primary source of Neotropical biodiversity,12 but it remains among the least known forests in America and is often underrepresented in biodiversity databases.13,14,15 To worsen this situation, human-induced modifications16,17 may eliminate pieces of the Amazon's biodiversity puzzle before we can use them to understand how ecological communities are responding. To increase generalization and applicability of biodiversity knowledge,18,19 it is thus crucial to reduce biases in ecological research, particularly in regions projected to face the most pronounced environmental changes. We integrate ecological community metadata of 7,694 sampling sites for multiple organism groups in a machine learning model framework to map the research probability across the Brazilian Amazonia, while identifying the region's vulnerability to environmental change. 15%–18% of the most neglected areas in ecological research are expected to experience severe climate or land use changes by 2050. This means that unless we take immediate action, we will not be able to establish their current status, much less monitor how it is changing and what is being lost

ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice

Digital anamorphosis is used to define a distorted image of health and care that may be viewed correctly using digital tools and strategies. MASK digital anamorphosis represents the process used by MASK to develop the digital transformation of health and care in rhinitis. It strengthens the ARIA change management strategy in the prevention and management of airway disease. The MASK strategy is based on validated digital tools. Using the MASK digital tool and the CARAT online enhanced clinical framework, solutions for practical steps of digital enhancement of care are proposed

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials